TSOL18 and TSOL45-1A provide the basis for development of a highly effective practical vaccine that could assist in the control and, potentially, the eradication of human neurocysticercosis. Cysticercosis in humans is caused by infection with the larval stage of the tapeworm parasite eggs derived from PF-06821497 the feces of a person infected with the adult tapeworm parasite. of the tapeworm parasite eggs derived from the feces of a person infected with the adult tapeworm parasite. The normal life cycle of the parasite involves transmission through pigs acting as intermediate hosts. Pigs develop cysticerci in their muscle tissues following ingestion of tapeworm eggs from the feces of a human tapeworm carrier. The life cycle is completed when incompletely cooked pig tissues containing cysticerci are eaten by a human, leading to the growth of the adult tapeworm in the small intestine. However, the tapeworm eggs not only are infective for pigs but also can infect humans, leading to the disease neurocysticercosis. Control of transmission of this disease can be achieved by improvements in public sanitation, particularly the provision and use of latrines (6, 7). Also, it is possible to remove the adult tapeworm by use of highly effective drugs, for example, praziquantel (30). Despite the availability of these methods for control of cysticercosis, the disease continues to be prevalent in many parts of the world. A potential additional method for control of this disease would be vaccination. Substantial progress has been made with the development of highly effective, PF-06821497 practical vaccines against closely related cestode parasites (19). Use of an effective vaccine in the natural animal intermediate hosts of would remove the source of tapeworm infection in humans, breaking the parasite’s life cycle and indirectly eliminating the causative agent of human neurocysticercosis. A number of approaches are being used by different groups towards the development of a vaccine against infection (2, 13, 32, 37). The approach that has been most successful in development of vaccines against other taeniid cestode parasites has been the use of recombinant oncosphere HSP90AA1 antigens (21). Three independently host-protective oncosphere antigens have been identified from (12, 14), and homologues of these proteins have been found to be host protective against infection with in cattle (25). Gauci and colleagues (8, 9) identified and cloned cDNAs encoding oncosphere proteins TSOL18 and TSOL45-1A, which are homologues of host-protective antigens in (To18 and To45W) (12, 14) and (TSA18 and TSA9) (25). Here we describe investigations into the use of recombinant oncosphere antigens as vaccines against challenge infection with in pigs. In order to utilize these proteins in vaccine trials, TSOL18 and TSOL45-1A cDNAs were PF-06821497 subcloned into expression vectors and fusion proteins were expressed in JM109. In oncospheres, the TSOL45 proteins are PF-06821497 encoded by a family of related genes that produce alternatively spliced mRNA transcripts (9). Since at least eight TSOL45-related proteins were identified in oncospheres, the transcript selected initially for expression and testing of the associated protein in vaccine trials was that which encoded a protein (referred to by Gauci and Lightowlers [9] as TSO45-1A) having the closest homology to the To45W protective antigen from JM109. Recombinant proteins were prepared by growth of the bacterial cultures overnight followed by 10-fold dilution into fresh culture medium (per liter, 20 g of tryptone, 5 g of yeast extract, 0.5 g of NaCl, 0.2 g of KCl, 2?g of MgCl2 [SOB] containing 100 g of ampicillin per ml), growth in shaker flasks until an optical density at 600 nm of 1 1.0 was reached, and induction with 0.2 mM IPTG (isopropyl–d-thiogalactopyranoside) for 5 h prior to purification of the glutathione JM109. The DNA sequences of cloned PCR amplification products were confirmed on both strands by using BigDye terminator cycle sequencing reactions (Applied Biosystems) and a PRISM automated sequencing system (Applied Biosystems). GST fusion proteins were prepared as described above. The nomenclature TSOL18 and TSOL45-1A was retained for these truncated recombinant proteins, which were used as GST fusion proteins in vaccination trials unless otherwise specified. For production of maltose binding protein (MBP) fusion proteins, the truncated TSOL18 and TSOL45-1A cDNAs were digested from pGEX with EcoRI and XhoI, purified as described above, subcloned into the EcoRI/SalI sites of pMAL-C2 (New England Biolabs), transformed.